Denosumab Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What External and Internal Drivers Are Contributing to the Growth of theDenosumab Market?
The denosumab market is set to experience growth due to the rising instances of osteoporosis. This medical condition, which weakens bones and increases the risk of fractures due to loss of bone density, is effectively treated with denosumab which targets RANK ligand to halt bone resorption. To illustrate, stats from the Canadian Longitudinal Study on Aging, reported by the National Center for Biotechnology Information, a US government agency in September 2023, showcased a 12.7% prevalence of osteoporosis with a physician’s diagnosis while osteoporosis confirmed through DXA stood at 5.9% among older adults living in the community. Furthermore, a study led by Buttros highlighted that out of postmenopausal women aged 40 to 75, 24.6% were diagnosed with osteoporosis after assessing bone mineral density (BMD) measurements. Hence, as the incidents of osteoporosis increase, it fuels the growth of the denosumab market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp
#What Growth Opportunities Will Drive the Denosumab Market’s CAGR Through 2034?
The market size of denosumab has witnessed a quick expansion in the past years. Its growth is projected to rise from $3.27 billion in 2024 to an impressive $3.7 billion in 2025, marking a compound annual growth rate (CAGR) of 13.1%. The notable increase during the historic period is due to valuable clinical trials and research developments, successful FDA approvals and regulatory achievements, amplified consciousness about bone health, along with strategic collaborations and marketing endeavors.
Anticipated expansion is expected in the denosumab market in the upcoming years, reaching a notable $5.59 billion by 2029, with a compound annual growth rate (CAGR) of 10.9%. Factors contributing to this growth during the forecast period include the escalating incidence of bone metastases, progress in cancer treatment methods, prevalent osteoporosis, heightened osteoporosis awareness, and regulatory acceptance for new indications. Key trends for the same period will be strategic alliances and collaborations, integration with digital health solutions, broader indications and clinical applications, and advancements in the development of biosimilars.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13835
Which Upcoming Market Trends and Innovations Are Set to Influence theDenosumab Market’s Path Forward?
Primary businesses in the denosumab market are intensifying their efforts to develop novel solutions like first-line osteoporosis treatments to establish an upper hand in the industry. A first-line treatment for osteoporosis is the preliminary procedure suggested by healthcare practitioners for individuals with an osteoporosis diagnosis. For example, in November 2022, China’s Boan Biotech received approval from the National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, making it the pioneer Chinese company to create a denosumab injection. The company is also venturing into markets outside China, such as Europe and the US, with a global marketing strategy. Several treatment guidelines consider the drug as a primary treatment for osteoporosis. The treatment holds significant promise in reducing the likelihood of hip, non-vertebral, and vertebral fractures among patients. Moreover, Boyoubei is the first biosimilar to Prolia (the original denosumab) to gain approval for global marketing.
Who Are the Dominant Market Players Pushing the Boundaries of theDenosumab Market?
Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report
What Are the Core Segments of the Denosumab Market, and How Do They Contribute to Growth?
The denosumab market covered in this report is segmented –
1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp
What Regions Are Dominating the Denosumab Market Growth?
North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Denosumab Market 2025, By The Business Research Company:
Antifungals Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report
Antiobesity Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report
Anemia And Other Blood Disorder Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
